The Impact of the UK COVID-19 Lockdown on the Screening, Diagnostics and Incidence of Breast, Colorectal, Lung and Prostate Cancer in the UK: a Population-Based Cohort Study

Nicola L Barclay, Marta Pineda Moncusi, Annika M. Jödicke, Daniel Prieto-Alhambra, Berta Raventós, Danielle Newby, Antonella Delmestri, Wai Yi Man, Xihang Chen, Marti Català.

Screening/ Diagnostic Test	Incidence Cohort
Breast	
Referral to breast clinic	Breast cancer referrals
Referral to mammography clinic	Breast cancer referrals
Fast track referral for suspected breast cancer	Breast cancer referrals
Referral to breast surgeon	Breast cancer referrals
Screening mammograms	Mammograms
Seen in breast clinic	Seen in breast clinic
Diagnostic mammograms	Mammograms
Diagnostic mammograms with ultrasound	Mammograms
Biopsy of breast	Biopsy of Breast
Stereotactically guided needle biopsy of breast	Biopsy of Breast
Percutaneous needle biopsy of breast	Biopsy of Breast
Fine needle aspiration of breast	Biopsy of Breast
Wire guided local excision of breast	Biopsy of Breast
Excision of mammary duct	Biopsy of Breast
Wide local excision of breast	Biopsy of Breast
Excision of breast tissue	Biopsy of Breast
Seen by breast surgeon	Seen by breast surgeon
Colorectal	
Colorectal cancer screening programme	Colorectal cancer screening programme
Fast-track referral for suspected colorectal cancer	Colorectal cancer referrals
Quantitative faecal immunochemical test	/
Ultrasonography of intestine	/
Colonoscopy	Colonoscopy
Sigmoidoscopy	Sigmoidoscopy
Ultrasound of gastrointestinal tract	/
Ultrasonography of abdomen	/
Ultrasonography of rectum	/
Lung	
Fast track referral for suspected lung cancer	Lung cancer referrals
Bronchoscopy	Bronchoscopy
Endobronchial ultrasonography guided	Diagnostic procedures of chest
transbronchial needle aspiration	
Mediastinoscopy	Diagnostic procedures of chest
CT and biopsy of chest	Diagnostic procedures of chest
Ultrasound and biopsy of chest	Diagnostic procedures of chest
Diagnostic radiology procedures of chest	Diagnostic procedures of chest
Prostate	
Prostate specific antigen (PSA) test	Prostate specific antigen (PSA) test
PSA monitoring	/
Biopsy of prostate	Biopsy of prostate

Supplementary Tables and Figures

Note. / = Tests/measurements/procedures that did not have sufficient counts in the CPRD GOLD database were not included in the incidence analyses.






Figure S1. Expected and observed incidence rates per 100,000 person months of A) breast cancer, B) colorectal cancer, C) lung cancer, and D) prostate cancer in primary care records from CPRD UK, from the validation model. Note. Points represent monthly incidence rates. Expected rates (with 95% prediction intervals) were calculated using negative binomial regression using observed data from January 2017 to February 2020 to estimate expected counts during the same period to validate the methodology. The shaded areas represent the 95% prediction intervals.








Figure S2. Expected and observed incidence rates per 100,000 person months of A) breast cancer, B) colorectal cancer, C) lung cancer, and D) prostate cancer in primary care records from CPRD UK, after lockdown, stratified by age and sex, from the validation model. Note. Points represent monthly incidence rates. Expected rates (with 95% prediction intervals) were calculated using negative binomial regression using observed data from January 2017 to February 2020 to estimate expected counts during the same period to validate the methodology. The shaded areas represent the 95% prediction intervals.

Denominator count (n)	Reason for exclusion	Excluded (n)
16,958,587	Starting population	NA
16,958,587	Missing year of birth	0
16,958,587	Missing sex	0
16,958,587	Cannot satisfy age criteria during the study period based on year of birth	0
5,694,486	No observation time available during study period (January 2017 to December 2021)	11,264,101
5,694,486	Doesn't satisfy age criteria during the study period	0
5,191,650	Prior history requirement not fulfilled during study period	502,836
5,191,268	Excluded due to prior breast cancer diagnosis (do not pass outcome washout during study period)	382
5,191,291	Excluded due to prior colorectal cancer diagnosis (do not pass outcome washout during study period)	359
5,191,131	Excluded due to prior lung cancer diagnosis (do not pass outcome washout during study period)	519
5,191,367	Excluded due to prior prostate cancer diagnosis (do not pass outcome washout during study period)	283

Table S2. Source population starting counts, final counts after applying excision criteria, and reasons for exclusion

Table S3. Proportion of source population in different age groups for those enrolled in CPRD GOLD before, during and after lockdown

Age Group	Proportion Pre-pandemic (Jan 2017-Feb 2020)	Proportion During Lockdown (March 2020-June 2020)	Proportion After lockdown (July 2020-Dec 2021)
0 to 9 years	24.45%	24.91%	24.46%
10 to 19 years	9.38%	9.09%	8.99%
20 to 29 years	15.09%	14.49%	15.71%
30 to 39 years	17.24%	17.46%	17.57%
40 to 49 years	13.16%	13.79%	13.38%
50 to 59 years	10.04%	10.54%	10.25%
60 to 69 years	6.41%	6.38%	6.2%
70 to 79 years	2.85%	2.44%	2.43%
80 to 89 years	1.07%	0.73%	0.79%
90 to 99 years	0.3%	0.16%	0.2%
100+ years	0.01%	0.01%	0.01%

Note. Counts before applying exclusion criteria




Figure S3. Proportion of source population observed in each region of the UK in the CPRD GOLD, for those enrolled before, during and after lockdown

N Pre-pandemic N During Lockdown N After lockdown Screening/Diagnostic Test (Jan 2017-Feb (March 2020-June (July 2020-Dec 2020) 2020) 2021) Visits in the healthcare system 184,471,700 12,108,287 74,106,599 Breast Referral to Breast clinic 31,079 1571 10,535 Referral to mammography clinic 1634 64 515 Fasttrack referral for suspected breast cancer 13,203 707 4277 Referral to breast surgeon 21,443 1014 7489 Seen in breast clinic 106,697 4114 28,463 4427 332 Seen by breast surgeon 116 124 Diagnostic mammograms 1139 14 Screening mammography 2295 78 160 Diagnostic mammogram and ultrasound 264,009 2561 46,480 **Biopsy of breast** 4906 293 1987 Stereotactically guided core needle biopsy of 1483 70 539 breast Percutaneous needle biopsy of breast 1555 71 556 Fine needle aspiration of breast 586 43 201 Wire guided local excision of breast lump 218 7 52 Excision of mammary duct 45 223 6 Wide local excision of breast lesion 3247 215 1038 Excision of lesion of breast 4888 275 1484 Excision of breast tissue 9652 2810 511 Colorectal Fast track referral for suspected colorectal 7977 472 2954 cancer Bowel cancer screening programme 10,172 275 3554 Quantitative faecal immunochemical tests 12 0 23 Screening colonoscopy 0 0 0 340 Colonoscopies <5 81

Table S4. Counts of healthcare visits, screening and diagnostic procedures, before, during and after lockdown (including descendant concepts) in the denominator population

Table S4. Counts of healthcare visits, screening and diagnostic procedures, before, during and after

 lockdown (including descendant concepts) in the denominator population

Screening/Diagnostic Test	N Pre-pandemic (Jan 2017-Feb 2020)	N During Lockdown (March 2020-June 2020)	N After lockdown (July 2020-Dec 2021)
Ultrasonography of intestine	0	0	0
Endoscopic ultrasound of upper gastrointestinal tract	124	<5	15
Ultrasound of gastrointestinal tract	124	<5	15
Ultrasonography of abdomen	18,303	532	4989
Ultrasonography of rectum	0	0	0
Sigmoidoscopy	234	<5	57
Lung			
Fast track referral for suspected lung cancer	2105	79	547
Bronchoscopy	133	5	22
Endobronchial ultrasonography guided transbronchial needle aspiration	0	0	0
Mediastinoscopy	106	5	23
Mediastinoscopy - inspection only	33	<5	12
CT and biopsy of chest	0	0	0
US scan and biopsy of chest	0	0	0
Diagnostic Radiology (Diagnostic Imaging) Procedures of the Chest	0	0	0
MRI of chest	394	19	110
Prostate			
PSA monitoring	2920	139	825
Prostate specific antigen measurement	521,564	21,683	177,358
PSA (prostate-specific antigen) level measurement	1055	24	219
Biopsy of prostate	3269	155	1052
Open biopsy of prostate	114	9	46

Note. Counts <5 masked to maintain patient confidentiality.

Table S5. Counts of healthcare visits, screening/ diagnostic tests and referrals, occurring in the month, ≤6 months, and >6 months prior to diagnosis date, for breast cancer patients diagnosed before, during and after lockdown

Screening/diagnostic test	Time window prior to diagnosis date	N Pre- pandemic (8,815)	N During Lockdown (459)	N After Lockdown (2,900)
Biopsy of breast	1 to 30 days	550	45	268
	31 to 180 days	87	5	37
	180+ days	335	14	113
Diagnostic mammogram & ultrasound	1 to 30 days	921	35	288
	31 to 180 days	397	14	79
	180+ days	12,161	663	3,876
Diagnostic mammograms	1 to 30 days	13	<5	<5
	31 to 180 days	5	0	<5
	180+ days	54	<5	13
Excision of breast tissue	1 to 30 days	206	10	62
	31 to 180 days	74	5	25
	180+ days	333	18	101
Excision of lesion of breast	1 to 30 days	153	6	41
	31 to 180 days	48	<5	16
	180+ days	227	11	57
Excision of mammary duct	1 to 30 days	<5	0	<5
	31 to 180 days	<5	0	0
	180+ days	23	<5	13
Fasttrack referral for suspected breast cancer	1 to 30 days	349	30	94
	31 to 180 days	182	10	74
	180+ days	87	8	22
Fine needle aspiration of breast	1 to 30 days	25	<5	13
	31 to 180 days	5	0	<5
	180+ days	100	<5	20
Percutaneous needle biopsy of breast	1 to 30 days	255	18	108
	31 to 180 days	36	<5	10

Table S5. Counts of healthcare visits, screening/ diagnostic tests and referrals, occurring in the month, ≤ 6 months, and >6 months prior to diagnosis date, for breast cancer patients diagnosed before, during and after lockdown

Screening/diagnostic test	Time window prior to diagnosis date	N Pre- pandemic (8,815)	N During Lockdown (459)	N After Lockdown (2,900)
	180+ days	58	<5	21
Referral to breast clinic	1 to 30 days	490	36	161
	31 to 180 days	419	25	185
	180+ days	559	28	228
Referral to breast surgeon	1 to 30 days	360	33	103
	31 to 180 days	295	13	120
	180+ days	290	26	110
Referral to mammography clinic	1 to 30 days	27	<5	11
	31 to 180 days	29	<5	11
	180+ days	56	<5	8
Screening mammography	1 to 30 days	12	0	0
	31 to 180 days	9	0	0
	180+ days	118	<5	9
Seen by breast surgeon	1 to 30 days	125	9	18
	31 to 180 days	37	5	<5
	180+ days	59	<5	21
Seen in breast clinic	1 to 30 days	2,437	129	663
	31 to 180 days	596	36	196
	180+ days	2,056	115	705
Stereotactically guided core needle biopsy	1 to 30 days	252	17	108
	31 to 180 days	36	<5	10
	180+ days	56	0	19
Visits within healthcare system	1 to 30 days	32,146	1,798	11,123
	31 to 180 days	87,799	4,389	30,649
	180+ days	2,340,878	126,691	827,739
Wide local excision of breast lesion	1 to 30 days	111	<5	31

Table S5. Counts of healthcare visits, screening/ diagnostic tests and referrals, occurring in the month, ≤6 months, and >6 months prior to diagnosis date, for breast cancer patients diagnosed before, during and after lockdown

Screening/diagnostic test	Time window prior to diagnosis date	N Pre- pandemic (8,815)	N During Lockdown (459)	N After Lockdown (2,900)
	31 to 180 days	34	<5	8
	180+ days	31	0	<5
Wire guided local excision of breast lump	1 to 30 days	10	<5	<5
	31 to 180 days	<5	0	<5
	180+ days	<5	0	<5

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021. Counts <5 masked to maintain patient confidentiality. **Table S6.** Counts of healthcare visits, screening and diagnostic procedures, occurring in the month, 6 months, and 6 months+, for colorectal cancer patients diagnosed before, during and after lockdown (including descendant concepts)

Screening/diagnostic test	Time window prior to index date	N Pre-pandemic (6,025)	N During Lockdown (349)	N After Lockdown (2,234)
Bowel cancer screening programme	1 to 30 days	14	0	<5
	31 to 180 days	38	<5	7
	180+ days	360	19	104
Colonoscopies	1 to 30 days	<5	0	0
	31 to 180 days	<5	0	<5
	180+ days	8	0	<5
Visits within healthcare system	1 to 30 days	28,556	1,722	11,472
	31 to 180 days	85,288	4,532	32,678
	180+ days	1,751,840	105,839	705,013

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021. There were no results for the following screening/diagnostic tests across these time-periods: Endoscopic ultrasound of upper gastrointestinal tract; Fast track referral for suspected colorectal cancer; Quantitative faecal immunochemical tests; Screening colonoscopies; Sigmoidoscopy; Ultrasonography of abdomen; Ultrasonography of intestine; Ultrasonography of rectum; Ultrasound of gastrointestinal tract. Counts <5 masked to maintain patient confidentiality. **Table S7.** Counts of healthcare visits, screening and diagnostic procedures, occurring in the month, 6 months, and 6 months+, for lung cancer patients diagnosed before, during and after lockdown (including descendant concepts)

Screening/diagnostic test	Time window prior to index date	N Pre-pandemic (5,766)	N During Lockdown (435)	N After Lockdown (2,102)
Bronchoscopy	1 to 30 days	0	<5	<5
	31 to 180 days	<5	0	0
	180+ days	<5	0	<5
Mediastinoscopy	1 to 30 days	<5	0	0
	31 to 180 days	<5	0	0
	180+ days	<5	0	<5
Visits within healthcare system	1 to 30 days	35,816	2,811	13,483
	31 to 180 days	98,896	7,452	35,804
	180+ days	2,056,404	164,494	825,358

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021. There were no results for the following screening/diagnostic tests across these time-periods: CT and biopsy of chest; Diagnostic Radiology (Diagnostic Imaging) Procedures of the Chest; Endobronchial ultrasonography guided transbronchial needle aspiration; Fast track referral for lung cancer; MRI of chest; US scan and biopsy of chest. Counts < masked to maintain patient confidentiality.

Table S8. Counts of healthcare visits, screening and diagnostic procedures, occurring in the month, 6 months, and 6 months+, for prostate cancer patients diagnosed before, during and after lockdown (including descendant concepts)

Screening/diagnostic test	Time window prior to index date	N Pre-pandemic (8,103)	N during lockdown (427)	N after lockdown (4,277)
Visits within healthcare system	1 to 30 days	32,686	1,734	10,956
	31 to 180 days	118,353	6,358	38,489
	180+ days	2,125,748	120,351	716,009

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021. There were no results for the following screening/diagnostic tests across these time-periods: Biopsy of prostate; Open biopsy of prostate; PSA monitoring; Prostate specific antigen measurement – level; Prostate specific antigen measurement.

	Pre-pandemic	During Lockdown	After Lockdown	Standa	rdised Mean Differences
Characteristic	Count (% of n=8,815)	Count (% of n=459)	Count (% of n=2,900)	Before vs. during lockdown	Before vs. after lockdown
Medical history: General					
Acute respiratory disease	374 (4.2)	15 (3.3)	46 (1.6)	-0.05	-0.16
Attention deficit hyperactivity disorder	<5 (~0)	0 (0)	0 (0)	-0.02	-0.02
Chronic liver disease	12 (0.1)	0 (0)	5 (0.2)	-0.05	0.01
Chronic obstructive lung disease	112 (1.3)	<5 (~0)	26 (0.9)	-0.12	-0.04
Crohn's disease	<5 (~0)	0 (0)	<5 (~0)	-0.03	0.00
Dementia	29 (0.3)	<5 (~0)	13 (0.4)	0.02	0.02
Depressive disorder	102 (1.2)	5 (1.1)	19 (0.7)	-0.01	-0.05
Diabetes mellitus	89 (1)	<5 (~0)	33 (1.1)	-0.10	0.01
Gastroesophageal reflux disease	27 (0.3)	<5 (~0)	11 (0.4)	0.02	0.01
Gastrointestinal hemorrhage	60 (0.7)	<5 (~1)	11 (0.4)	0.02	-0.04
Hyperlipidemia	43 (0.5)	<5 (~0)	<5 (0.1)	-0.05	-0.06
Hypertensive disorder	141 (1.6)	5 (1.1)	44 (1.5)	-0.04	-0.01
Lesion of liver	29 (0.3)	0 (0)	12 (0.4)	-0.08	0.01
Obesity	18 (0.2)	<5 (~0)	<5 (~0)	0.00	-0.02
Osteoarthritis	195 (2.2)	6 (1.3)	39 (1.3)	-0.07	-0.07
Pneumonia	39 (0.4)	<5 (~0)	13 (0.4)	-0.04	0.00
Psoriasis	47 (0.5)	<5 (~1)	9 (0.3)	0.02	-0.03
Renal impairment	100 (1.1)	5 (1.1)	31 (1.1)	0.00	-0.01

	Pre-pandemic	During Lockdown	After Lockdown	Standa	rdised Mean Differences
Characteristic	Count (% of n=8,815)	Count (% of n=459)	Count (% of n=2,900)	Before vs. during lockdown	Before vs. after lockdown
Rheumatoid arthritis	18 (0.2)	<5 (~0)	7 (0.2)	0.00	0.01
Schizophrenia	<5 (~0)	0 (0)	<5 (~0)	-0.02	0.02
Ulcerative colitis	7 (0.1)	0 (0)	<5 (~0)	-0.04	-0.02
Urinary tract infectious disease	212 (2.4)	7 (1.5)	53 (1.8)	-0.06	-0.04
Visual system disorder	415 (4.7)	24 (5.2)	88 (3)	0.02	-0.09
Medical history: Cardiovas	scular disease				
Atrial fibrillation	53 (0.6)	<5 (~1)	14 (0.5)	0.03	-0.02
Cerebrovascular disease	33 (0.4)	0 (0)	8 (0.3)	-0.09	-0.02
Coronary arteriosclerosis	<5 (~0)	0 (0)	<5 (~0)	-0.03	-0.01
Heart disease	153 (1.7)	10 (2.2)	45 (1.6)	0.03	-0.01
Heart failure	21 (0.2)	<5 (~1)	7 (0.2)	0.06	0.00
Ischemic heart disease	31 (0.4)	<5 (~1)	14 (0.5)	0.01	0.02
Peripheral vascular disease	12 (0.1)	0 (0)	<5 (~0)	-0.05	0.00
Pulmonary embolism	18 (0.2)	0 (0)	11 (0.4)	-0.06	0.03
Venous thrombosis	57 (0.6)	0 (0)	14 (0.5)	-0.11	-0.02
Medical history: Neo	oplasms				
Hematologic neoplasm	40 (0.5)	0 (0)	21 (0.7)	-0.10	0.04
Malignant lymphoma	8 (0.1)	<5 (~0)	<5 (~0)	0.03	0.01
Malignant neoplasm of anorectum	11 (0.1)	0 (0)	<5 (~0)	-0.05	-0.02

	Pre-pandemic	During Lockdown	After Lockdown	Standa	rdised Mean Differences
Characteristic	Count (% of n=8,815)	Count (% of n=459)	Count (% of n=2,900)	Before vs. during lockdown	Before vs. after lockdown
Malignant neoplastic disease	8815 (100)	459 (100)	2900 (100)	/	/
Malignant tumor of breast	8815 (100)	459 (100)	2900 (100)	/	/
Malignant tumor of colon	12 (0.1)	0 (0)	<5 (~0)	-0.05	-0.02
Malignant tumor of lung	29 (0.3)	<5 (~1)	9 (0.3)	0.05	0.00
Malignant tumor of urinary bladder	<5 (~0)	0 (0)	<5 (~0)	-0.03	0.00
Medication use					
Agents acting on the renin-angiotensin system	1967 (22.3)	94 (20.5)	650 (22.4)	-0.04	0.00
Antibacterials for systemic use	3783 (42.9)	212 (46.2)	1129 (38.9)	0.07	-0.08
Antidepressants	2388 (27.1)	119 (25.9)	807 (27.8)	-0.03	0.02
Antiepileptics	659 (7.5)	42 (9.2)	207 (7.1)	0.06	-0.01
Antiinflammatory and antirheumatic products	2662 (30.2)	128 (27.9)	774 (26.7)	-0.05	-0.08
Antineoplastic agents	139 (1.6)	5 (1.1)	39 (1.3)	-0.04	-0.02
Antipsoriatics	427 (4.8)	26 (5.7)	137 (4.7)	0.04	-0.01
Antithrombotic agents	1329 (15.1)	63 (13.7)	446 (15.4)	-0.04	0.01
Beta blocking agents	1330 (15.1)	54 (11.8)	427 (14.7)	-0.10	-0.01
Calcium channel blockers	1311 (14.9)	61 (13.3)	476 (16.4)	-0.05	0.04

	Pre-pandemic	During Lockdown	After Lockdown	Standa	rdised Mean Differences
Characteristic	Count (% of n=8,815)	Count (% of n=459)	Count (% of n=2,900)	Before vs. during lockdown	Before vs. after lockdown
Diuretics	1417 (16.1)	66 (14.4)	423 (14.6)	-0.05	-0.04
Drugs for acid related disorders	3433 (38.9)	162 (35.3)	1138 (39.2)	-0.08	0.01
Drugs for obstructive airway diseases	2498 (28.3)	128 (27.9)	766 (26.4)	-0.01	-0.04
Drugs used in diabetes	643 (7.3)	31 (6.8)	210 (7.2)	-0.02	0.00
Immunosuppressants	126 (1.4)	<5 (~1)	28 (1)	-0.08	-0.04
Lipid modifying agents	2191 (24.9)	95 (20.7)	676 (23.3)	-0.10	-0.04
Opioids	2443 (27.7)	120 (26.1)	758 (26.1)	-0.04	-0.04
Psycholeptics	1524 (17.3)	88 (19.2)	451 (15.6)	0.05	-0.05
Psychostimulants	<5 (~0)	0 (0)	<5 (~0)	-0.02	0.04
Comorbidity Scales	Mean (SD)	Mean (SD)	Mean (SD)	Std.Diff	Std.Diff
Charlson comorbidity index	2.8 (1.4)	2.7 (1.3)	2.8 (1.4)	-0.05	-0.02
CHADS2Vasc	2.1 (1.3)	2.1 (1.3)	2.1 (1.3)	-0.02	0.01
DCSI	0.7 (1.5)	0.6 (1.5)	0.7 (1.5)	-0.03	-0.01

Note. CHADS2Vasc: Comborbidity scale measuring congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, age and sex. DCSI: Diabetes Complications and Severity Index. SD = Standard Deviation. Counts <5 masked and proportions rounded to nearest 1% in order for frequencies <5 to remain masked. Bold indicates significant standardised mean differences between lockdown periods (>.10).

	Pre-pandemic	During Lockdown	After Lockdown		ised Mean Differences
Characteristic	Count (% of n=6,025)	Count (% of n=349)	Count (% of n=2,234)	Before vs. during lockdown	Before vs afte lockdowr
Medical history: General		· · ·			
Acute respiratory disease	232 (3.9)	10 (2.9)	46 (2.1)	-0.05	-0.1
Chronic liver disease	16 (0.3)	<5 (~0)	7 (0.3)	0.00	0.0
Chronic obstructive lung disease	128 (2.1)	10 (2.9)	33 (1.5)	0.05	-0.0
Crohn's disease	<5 (~0)	<5 (~0)	5 (~0)	0.05	0.0
Dementia	44 (0.7)	<5 (~1)	15 (0.7)	0.01	-0.0
Depressive disorder	60 (1)	6 (1.7)	10 (0.4)	0.06	-0.0
Diabetes mellitus	110 (1.8)	8 (2.3)	36 (1.6)	0.03	-0.0
Gastroesophageal reflux disease	35 (0.6)	<5 (~0)	5 (0.2)	-0.04	-0.0
Gastrointestinal hemorrhage	610 (10.1)	23 (6.6)	163 (7.3)	-0.13	-0.1
Hyperlipidemia	17 (0.3)	<5 (~0)	9 (0.4)	0.00	0.0
Hypertensive disorder	83 (1.4)	5 (1.4)	27 (1.2)	0.00	-0.0
Lesion of liver	193 (3.2)	19 (5.4)	102 (4.6)	0.11	0.0
Obesity	17 (0.3)	0 (0)	8 (0.4)	-0.08	0.0
Osteoarthritis	141 (2.3)	12 (3.4)	26 (1.2)	0.07	-0.0
Pneumonia	51 (0.8)	<5 (~1)	21 (0.9)	0.00	0.0
Psoriasis	20 (0.3)	<5 (~0)	7 (0.3)	-0.01	0.0
Renal impairment	167 (2.8)	9 (2.6)	36 (1.6)	-0.01	-0.0
Rheumatoid arthritis	10 (0.2)	<5 (0.3)	<5 (0.2)	0.03	0.0
Schizophrenia	<5 (~0)	0 (0)	0 (0)	-0.03	-0.0
Ulcerative colitis	9 (0.1)	<5 (~1)	<5 (~0)	0.10	0.0
Urinary tract infectious disease	136 (2.3)	9 (2.6)	37 (1.7)	0.02	-0.0
Visual system disorder	375 (6.2)	16 (4.6)	76 (3.4)	-0.07	-0.1

	Pre-pandemic	During Lockdown	After Lockdown	Standardis Di	sed Mean ifferences
Characteristic	Count (% of n=6,025)	Count (% of n=349)	Count (% of n=2,234)	Before vs. during lockdown	Before vs. after lockdown
Medical history: Cardiovascular diseas	e				
Atrial fibrillation	142 (2.4)	10 (2.9)	60 (2.7)	0.0	0.02
Cerebrovascular disease	61 (1)	8 (2.3)	23 (1)	0.1	. 0 0.00
Coronary arteriosclerosis	15 (0.2)	0 (0)	<5 (~0)	-0.0	07 -0.04
Heart disease	333 (5.5)	25 (7.2)	133 (6)	0.0	0.02
Heart failure	43 (0.7)	<5 (~1)	18 (0.8)	0.0	0.01
Ischemic heart disease	92 (1.5)	<5 (~1)	33 (1.5)	-0.0	0.00
Peripheral vascular disease	19 (0.3)	<5 (~1)	5 (0.2)	0.0	04 -0.02
Pulmonary embolism	62 (1)	<5 (~1)	25 (1.1)	0.0	0.01
Venous thrombosis	66 (1.1)	<5 (~1)	26 (1.2)	0.0	0 0.01
Medical history: Neoplasms					
Hematologic neoplasm	13 (0.2)	<5 (~1)	5 (0.2)	0.09	0.00
Malignant lymphoma	7 (0.1)	<5 (~0)	<5 (~0)	0.04	-0.01
Malignant neoplasm of anorectum	1767 (29.3)	94 (26.9)	642 (28.7)	-0.05	-0.01
Malignant neoplastic disease	6025 (100)	349 (100)	2234 (100)	/	/
Malignant tumor of breast	17 (0.3)	0 (0)	6 (0.3)	-0.08	0.00
Malignant tumor of colon	3866 (64.2)	223 (63.9)	1439 (64.4)	-0.01	0.01
Malignant tumor of lung	49 (0.8)	5 (1.4)	17 (0.8)	0.06	-0.01
Malignant tumor of urinary bladder	8 (0.1)	<5 (~1)	<5 (~0)	0.07	-0.01
Medication use					
Agents acting on the renin- angiotensin system	2134 (35.4)	118 (33.8)	707 (31.6)	-0.03	-0.08
Antibacterials for systemic use	2686 (44.6)	146 (41.8)	876 (39.2)	-0.06	-0.11

	Pre-pandemic	During	After	Standardised Me			
		Lockdown	Lockdown	C	Differences		
Characteristic	Count (% of n=6,025)	Count (% of n=349)	n=2,234)	Before vs. during lockdown	Before vs. after lockdown		
Antidepressants	1219 (20.2)	88 (25.2)	490 (21.9)	0.12	0.04		
Antiepileptics	438 (7.3)	32 (9.2)	166 (7.4)	0.07	0.01		
Antiinflammatory and antirheumatic products	2041 (33.9)	96 (27.5)	634 (28.4)	-0.14	-0.12		
Antineoplastic agents	133 (2.2)	6 (1.7)	47 (2.1)	-0.04	-0.01		
Antipsoriatics	1243 (20.6)	74 (21.2)	503 (22.5)	0.01	0.05		
Antithrombotic agents	1807 (30)	105 (30.1)	681 (30.5)	0.00	0.01		
Beta blocking agents	1393 (23.1)	74 (21.2)	489 (21.9)	-0.05	-0.03		
Calcium channel blockers	1480 (24.6)	85 (24.4)	525 (23.5)	0.00	-0.02		
Diuretics	1398 (23.2)	83 (23.8)	444 (19.9)	0.01	-0.08		
Drugs for acid related disorders	2912 (48.3)	159 (45.6)	1076 (48.2)	-0.06	0.00		
Drugs for obstructive airway diseases	1775 (29.5)	103 (29.5)	638 (28.6)	0.00	-0.02		
Drugs used in diabetes	782 (13)	50 (14.3)	326 (14.6)	0.04	0.05		
Immunosuppressants	95 (1.6)	7 (2)	39 (1.7)	0.03	0.01		
Lipid modifying agents	2438 (40.5)	154 (44.1)	930 (41.6)	0.07	0.02		
Opioids	1865 (31)	123 (35.2)	653 (29.2)	0.09	-0.04		
Psycholeptics	987 (16.4)	57 (16.3)	331 (14.8)	0.00	-0.04		
Psychostimulants, agents used for adhd and nootropics	<5 (~0)	0 (0)	<5 (~0)	-0.03	0.01		
Comorbidity Scales	Mean (SD)	Mean (SD)	Mean (SD)	Std.Diff	Std.Diff		
Charlson comorbidity index Mean	3.4 (1.9)	3.7 (2.3)	3.5 (2.1)	0.09	0.04		
CHADS2Vasc	2.3 (1.5)	2.3 (1.5)	2.3 (1.5)	-0.01	-0.01		
DCSI	1.3 (1.6)	1.3 (1.7)	1.3 (1.6)	0.02	0.01		

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021; CHADS2Vasc: Comborbidity scale measuring congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, age and sex. DCSI: Diabetes Complications and Severity Index. SD = Standard Deviation. Counts <5 masked and proportions rounded to nearest 1% in order for frequencies <5 to remain masked. Bold indicates significant standardised mean differences between lockdown periods (>.10).

Table S11. Characterizat	ion of lung patients diagnos	sed before, during and a	fter lockdown	-	
	Pre-pandemic	During Lockdown	After Lockdown		tandardised Differences
Characteristic	Count (% of n = 5,766)	Count (% of n=435)	Count (% of n = 2,102)	Before vs. during lockdown	Before vs. after lockdown
Medical history: Gener	al				
Acute respiratory disease	679 (11.8)	42 (9.7)	134 (6.4)	-0.07	-0.19
Chronic liver disease	12 (0.2)	<5 (~0)	<5 (~0)	0.00	-0.02
Chronic obstructive lung disease	727 (12.6)	58 (13.3)	199 (9.5)	0.02	-0.10
Crohn's disease	7 (0.1)	0 (0)	<5 (~0)	-0.05	-0.03
Dementia	62 (1.1)	<5 (~0)	11 (0.5)	-0.11	-0.06
Depressive disorder	82 (1.4)	7 (1.6)	19 (0.9)	0.02	-0.05
Diabetes mellitus	129 (2.2)	7 (1.6)	46 (2.2)	-0.05	0.00
Gastroesophageal reflux disease	34 (0.6)	<5 (~0)	14 (0.7)	-0.02	0.01
Gastrointestinal hemorrhage	68 (1.2)	5 (1.1)	15 (0.7)	0.00	-0.05
Hyperlipidemia	22 (0.4)	0 (0)	<5 (~0)	-0.09	0.03
Hypertensive disorder	89 (1.5)	8 (1.8)	15 (0.7)	0.02	0.05
Lesion of liver	144 (2.5)	12 (2.8)	27 (1.3)	0.02	-0.02
Obesity	10 (0.2)	0 (0)	47 (2.2)	-0.06	-0.02
Osteoarthritis	156 (2.7)	7 (1.6)	<5 (~0)	-0.08	-0.02

	Pre-pandemic	During Lockdown	After Lockdown		tandardised Differences
Characteristic	Count (% of n = 5,766)	Count (% of n=435)	Count (% of n = 2,102)	Before vs. during lockdown	Before vs. after lockdown
Pneumonia	219 (3.8)	24 (5.5)	52 (2.5)	0.08	-0.01
Psoriasis	30 (0.5)	<5 (~1)	78 (3.7)	0.02	0.00
Renal impairment	152 (2.6)	13 (3)	14 (0.7)	0.02	0.02
Rheumatoid arthritis	22 (0.4)	0 (0)	59 (2.8)	-0.09	0.01
Schizophrenia	<5 (~0)	0 (0)	7 (0.3)	-0.03	-0.01
Ulcerative colitis	<5 (~0)	0 (0)	0 (0)	-0.04	-0.03
Urinary tract infectious disease	145 (2.5)	7 (1.6)	<5 (~0)	-0.06	0.01
Viral hepatitis C	0 (0)	<5 (~0)	38 (1.8)	0.07	-0.05
Visual system disorder	420 (7.3)	29 (6.7)	105 (5)	-0.02	-0.10
Medical history: Cardio disease	vascular				
Atrial fibrillation	181 (3.1)	18 (4.1)	61 (2.9)	0.05	-0.01
Cerebrovascular disease	104 (1.8)	10 (2.3)	44 (2.1)	0.03	0.02
Coronary arteriosclerosis	11 (0.2)	<5 (~1)	<5 (~0)	0.05	0.00
Heart disease	421 (7.3)	36 (8.3)	179 (8.5)	0.04	0.05
Heart failure	76 (1.3)	6 (1.4)	37 (1.8)	0.01	0.04
Ischemic heart disease	109 (1.9)	8 (1.8)	49 (2.3)	0.00	0.03
Peripheral vascular disease	59 (1)	6 (1.4)	19 (0.9)	0.03	-0.01
Pulmonary embolism	120 (2.1)	13 (3)	46 (2.2)	0.06	0.01

Fable S11. Characterizati	on of lung patients diagnos	ed before, during and a	fter lockdown		
	Pre-pandemic	During Lockdown	After Lockdown		Standardised n Differences
Characteristic	Count (% of n = 5,766)	Count (% of n=435)	Count (% of n = 2,102)	Before vs. during lockdown	Before vs. after lockdown
Venous thrombosis	79 (1.4)	<5 (~1)	20 (1)	-0.07	-0.04
Medical history: Neoplasms					
Hematologic neoplasm	43 (0.7)	5 (1.1)	13 (0.6)	0.04	-0.02
Malignant lymphoma	10 (0.2)	<5 (~0)	9 (0.4)	0.01	0.05
Malignant neoplasm of anorectum	14 (0.2)	<5 (~1)	10 (0.5)	0.09	0.04
Malignant neoplastic disease	5766 (100)	435 (100)	2102 (100)	/	/
Malignant tumor of breast	33 (0.6)	<5 (~0)	17 (0.8)	-0.02	0.03
Malignant tumor of colon	29 (0.5)	<5 (~0)	11 (0.5)	-0.01	0.00
Malignant tumor of lung	5766 (100)	435 (100)	2102 (100)	/	/
Malignant tumor of urinary bladder	16 (0.3)	5 (1.1)	9 (0.4)	0.10	0.03
Medication use					
Agents acting on the renin-angiotensin system	2075 (36)	146 (33.6)	731 (34.8)	-0.05	-0.03
Antibacterials for systemic use	3955 (68.6)	292 (67.1)	1321 (62.8)	-0.03	-0.12
Antidepressants	1819 (31.5)	151 (34.7)	702 (33.4)	0.07	0.04
Antiepileptics	776 (13.5)	46 (10.6)	275 (13.1)	-0.09	-0.01
Antiinflammatory and antirheumatic products	2775 (48.1)	200 (46)	905 (43.1)	-0.04	-0.10

Table S11. Characterizati	on of lung patients diagnos		-	<u> </u>	
	Pre-pandemic	During Lockdown	After Lockdown		tandardised Differences
Characteristic	Count (% of n = 5,766)	Count (% of n=435)	Count (% of n = 2,102)	Before vs. during lockdown	Before vs. after lockdown
Antineoplastic agents	160 (2.8)	15 (3.4)	67 (3.2)	0.04	0.02
Antipsoriatics	490 (8.5)	38 (8.7)	232 (11)	0.01	0.09
Antithrombotic agents	2434 (42.2)	175 (40.2)	880 (41.9)	-0.04	-0.01
Beta blocking agents	1402 (24.3)	109 (25.1)	524 (24.9)	0.02	0.01
Calcium channel blockers	1564 (27.1)	111 (25.5)	574 (27.3)	-0.04	0.00
Diuretics	1507 (26.1)	104 (23.9)	502 (23.9)	-0.05	-0.05
Drugs for acid related disorders	3416 (59.2)	260 (59.8)	1305 (62.1)	0.01	0.06
Drugs for obstructive airway diseases	3132 (54.3)	231 (53.1)	1118 (53.2)	-0.02	-0.02
Drugs used in diabetes	774 (13.4)	47 (10.8)	301 (14.3)	-0.08	0.03
Immunosuppressants	138 (2.4)	11 (2.5)	60 (2.9)	0.01	0.03
Lipid modifying agents	2909 (50.5)	216 (49.7)	1101 (52.4)	-0.02	0.04
Opioids	3014 (52.3)	241 (55.4)	1059 (50.4)	0.06	-0.04
Psycholeptics	1441 (25)	112 (25.7)	521 (24.8)	0.02	0.00
Comorbidity Scales	Mean (SD)	Mean (SD)	Mean (SD)	Std.Diff	Std.Diff
Charlson comorbidity index	4.0 (2.2)	4.0 (2.2)	4.1 (2.3)	0.00	0.05
CHADS2Vasc	2.6 (1.5)	2.7 (1.5)	2.7 (1.5)	0.03	0.02
DCSI	1.6 (1.7)	1.6 (1.7)	1.6 (1.6)	0.03	0.02

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021; CHADS2Vasc: Comborbidity scale measuring congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, age and sex. DCSI: Diabetes Complications and Severity Index. SD = Standard Deviation. Counts <5 masked and proportions rounded to nearest 1% in order for frequencies <5 to remain masked. Bold indicates significant standardised mean differences between lockdown periods (>.10).

	Pre-pandemic	During Lockdown	After Lockdown		ised Mean Differences
Characteristic	Count (% of n=8,101)	Count (% of n=427)	Count of % n=2,476)	Before vs. during lockdown	Before vs. after lockdown
Medical history: General					
Acute respiratory disease	274 (3.4)	14 (3.3)	46 (1.9)	-0.01	-0.10
Attention deficit hyperactivity disorder	<5 (~0)	0 (0)	0 (0)	-0.02	-0.02
Chronic liver disease	<5 (~0)	<5 (~1)	5 (0.2)	0.08	0.04
Chronic obstructive lung disease	176 (2.2)	5 (1.2)	26 (1)	-0.08	-0.09
Crohn's disease	5 (0.1)	0 (0)	<5 (~0)	-0.04	-0.01
Dementia	35 (0.4)	0 (0)	10 (0.4)	-0.09	0.00
Depressive disorder	69 (0.9)	<5 (~1)	10 (0.4)	-0.05	-0.06
Diabetes mellitus	169 (2.1)	16 (3.7)	33 (1.3)	0.10	-0.06
Gastroesophageal reflux disease	37 (0.5)	0 (0)	13 (0.5)	-0.10	0.02
Gastrointestinal hemorrhage	81 (1)	<5 (~1)	16 (0.6)	-0.03	-0.04
Human immunodeficiency virus infection	<5 (~0)	0 (0)	0 (0)	-0.02	-0.02
Hyperlipidemia	55 (0.7)	<5 (~0)	8 (0.3)	-0.07	-0.05
Hypertensive disorder	223 (2.8)	10 (2.3)	46 (1.9)	-0.03	-0.06
Lesion of liver	15 (0.2)	5 (1.2)	16 (0.6)	0.12	0.07
Obesity	12 (0.1)	0 (0)	6 (0.2)	-0.05	0.02
Osteoarthritis	234 (2.9)	11 (2.6)	54 (2.2)	-0.02	-0.05
Pneumonia	51 (0.6)	<5 (~1)	13 (0.5)	-0.02	-0.02
Psoriasis	39 (0.5)	0 (0)	<5 (~0)	-0.10	-0.0

	Pre-pandemic	During Lockdown	After Lockdown		ised Mean Differences
Characteristic	Count (% of n=8,101)	Count (% of n=427)	Count of % n=2,476)	Before vs. during lockdown	Before vs. after lockdown
Renal impairment	258 (3.2)	9 (2.1)	63 (2.5)	-0.07	-0.04
Rheumatoid arthritis	8 (0.1)	<5 (~0)	<5 (~0)	0.03	-0.02
Ulcerative colitis	<5 (~0)	0 (0)	<5 (~0)	-0.02	0.01
Urinary tract infectious disease	227 (2.8)	12 (2.8)	58 (2.3)	0.00	-0.03
Visual system disorder	482 (5.9)	28 (6.6)	104 (4.2)	0.03	-0.08
Medical history: Cardiova	scular disease				
Atrial fibrillation	161 (2)	10 (2.3)	35 (1.4)	0.02	-0.04
Cerebrovascular disease	76 (0.9)	5 (1.2)	18 (0.7)	0.02	-0.02
Coronary arteriosclerosis	13 (0.2)	<5 (~0)	<5 (~0)	0.02	-0.01
Heart disease	351 (4.3)	18 (4.2)	92 (3.7)	-0.01	-0.03
Heart failure	66 (0.8)	<5 (~1)	12 (0.5)	0.01	-0.04
Ischemic heart disease	78 (1)	<5 (~1)	25 (1)	-0.03	0.00
Peripheral vascular disease	29 (0.4)	<5 (~1)	5 (0.2)	0.02	-0.03
Pulmonary embolism	31 (0.4)	<5 (~1)	17 (0.7)	0.01	0.04
Venous thrombosis	72 (0.9)	8 (1.9)	23 (0.9)	0.08	0.00
Medical history: Neoplasr	ns				
Hematologic neoplasm	30 (0.4)	<5 (~1)	10 (0.4)	0.07	0.01
Malignant lymphoma	5 (0.1)	0 (0)	<5 (~0)	-0.04	0.01
Malignant neoplasm of anorectum	15 (0.2)	<5 (~1)	6 (0.2)	0.05	0.01

	Pre-pandemic	During Lockdown	After Lockdown		ised Mean Differences
Characteristic	Count (% of n=8,101)	Count (% of n=427)	Count of % n=2,476)	Before vs. during lockdown	Before vs. after lockdown
Malignant neoplastic disease	8103 (100)	427 (100)	2477 (100)	/	/
Malignant tumor of breast	0 (0)	0 (0)	0 (0)	-0.03	-0.03
Malignant tumor of colon	10 (0.1)	0 (0)	7 (0.3)	-0.05	0.04
Malignant tumor of lung	17 (0.2)	<5 (~1)	7 (0.3)	0.04	0.01
Malignant tumor of urinary bladder	47 (0.6)	5 (1.2)	18 (0.7)	0.06	0.02
Medication use					
Agents acting on the renin-angiotensin system	3122 (38.5)	161 (37.7)	891 (36)	-0.02	-0.05
Antibacterials for systemic use	3682 (45.4)	195 (45.7)	1064 (43)	0.00	-0.05
Antidepressants	1162 (14.3)	54 (12.6)	400 (16.1)	-0.05	0.05
Antiepileptics	475 (5.9)	31 (7.3)	161 (6.5)	0.06	0.03
Antiinflammatory and antirheumatic products	3068 (37.9)	141 (33)	884 (35.7)	-0.10	-0.05
Antineoplastic agents	201 (2.5)	15 (3.5)	73 (2.9)	0.06	0.03
Antipsoriatics	402 (5)	19 (4.4)	121 (4.9)	-0.02	0.00
Antithrombotic agents	2622 (32.4)	128 (30)	829 (33.5)	-0.05	0.02
Beta blocking agents	1806 (22.3)	106 (24.8)	532 (21.5)	0.06	-0.02
Calcium channel blockers	2304 (28.4)	118 (27.6)	673 (27.2)	-0.02	-0.03
Diuretics	1425 (17.6)	66 (15.5)	394 (15.9)	-0.06	-0.04

	Pre-pandemic	During Lockdown	After Lockdown	Standardised Mean Differences		
Characteristic	Count (% of n=8,101)	Count (% of n=427)	Count of % n=2,476)	Before vs. during lockdown	Before vs. after lockdown	
Drugs for acid related disorders	3317 (40.9)	170 (39.8)	1060 (42.8)	-0.02	0.04	
Drugs for obstructive airway diseases	2352 (29)	106 (24.8)	700 (28.3)	-0.09	-0.02	
Drugs used in diabetes	891 (11)	58 (13.6)	273 (11)	0.08	0.00	
Immunosuppressants	113 (1.4)	9 (2.1)	31 (1.3)	0.05	-0.01	
Lipid modifying agents	3726 (46)	201 (47.1)	1152 (46.5)	0.02	0.01	
Opioids	2111 (26.1)	125 (29.3)	667 (26.9)	0.07	0.02	
Psycholeptics	830 (10.2)	46 (10.8)	279 (11.3)	0.02	0.03	
Psychostimulants, agents used for adhd and nootropics	<5 (~0)	0 (0)	0 (0)	-0.02	-0.02	
Comorbidity Scales	Mean (SD)	Mean (SD)	Mean (SD)	Std.Diff	Std.Diff	
Charlson comorbidity index	3.2 (1.7)	3.2 (1.7)	3.2 (1.7)	0.03	0.03	
CHADS2Vasc	1.9 (1.3)	1.8 (1.3)	1.9 (1.3)	-0.01	0.02	
DCSI	1.2 (1.5)	1.2 (1.4)	1.1 (1.5)	0.02	-0.02	

Note. Pre-pandemic = Jan 2017-Feb 2020; During Lockdown = March 2020-June 2020; After lockdown = July 2020-Dec 2021; CHADS2Vasc: Comborbidity scale measuring congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, age and sex. DCSI: Diabetes Complications and Severity Index. SD = Standard Deviation. Counts <5 masked and proportions rounded to nearest 1% in order for frequencies <5 to remain masked. Bold indicates significant standardised mean differences between lockdown periods (>.10).

Table S13. Incidence rates (with 95% confidence intervals) of screening and diagnostic tests across extended lockdown periods

Screening/Diagnostic Test	Pre-pandemic (Jan 2017-Feb 2020)	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021	Legal restrictions removed (July 2021-Dec 2021)
Biopsy of Breast	2.5 (2.4 to 2.6)	1.9 (1.7 to 2.1)	2.9 (2.8 to 3.1)	2.3 (2 to 2.6)	2.5 (2.2 to 3)	3 (2.5 to 3.4)	3.4 (3.1 to 3.7)	3.3 (3 to 3.6)
Biopsy Of Prostate	1.7 (1.7 to 1.8)	1.2 (1 to 1.4)	1.7 (1.5 to 1.8)	1.2 (1 to 1.4)	1.9 (1.5 to 2.2)	1.7 (1.4 to 2)	1.9 (1.6 to 2.1)	1.8 (1.6 to 2)
Bowel Cancer Screening Prog	0.2 (0.1 to 0.2)	NR	0.2 (0.2 to 0.3)	NR	NR	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)
Breast Cancer Referrals	27.3 (27 to 27.6)	17.5 (16.8 to 18.3)	25.1 (24.7 to 25.6)	24.8 (24 to 25.7)	25.7 (24.4 to 26.9)	23.6 (22.4 to 24.8)	26.1 (25.2 to 27)	25 (24.2 to 25.8)
Bronchoscopy	0.2 (0.1 to 0.2)	NR	NR	NR	NR	NR	NR	NR
Colonoscopy	35.7 (35.4 to 36)	12.6 (12 to 13.2)	26.3 (25.9 to 26.7)	20.2 (19.4 to 21)	26.1 (24.8 to 27.4)	27.2 (25.9 to 28.5)	30.1 (29.1 to 31)	28.3 (27.5 to 29.1)
Colorectal Cancer Referrals	19.9 (19.7 to 20.1)	11.5 (11 to 12.1)	18.5 (18.2 to 18.9)	17.7 (17 to 18.5)	17.7 (16.7 to 18.8)	16.5 (15.5 to 17.6)	20.4 (19.6 to 21.2)	19 (18.3 to 19.7)
Diagnostic Procedures Of Chest	0.2 (0.1 to 0.2)	NR	0.2 (0.1 to 0.4)	NR	NR	NR	NR	0.2 (0.1 to 0.4)
Excision Of Breast	4.9 (4.7 to 5)	3.5 (3.2 to 3.8)	4.2 (4.1 to 4.4)	3.6 (3.2 to 3.9)	5 (4.4 to 5.6)	3.9 (3.4 to 4.4)	4.5 (4.1 to 4.9)	4.5 (4.2 to 4.9)
Lung Cancer Referrals	1.2 (1.1 to 1.2)	0.6 (0.5 to 0.7)	0.8 (0.7 to 0.9)	0.8 (0.7 to 1)	0.7 (0.5 to 0.9)	0.8 (0.6 to 1)	1 (0.8 to 1.2)	0.8 (0.6 to 0.9)
Mammograms	79.1 (78.6 to 79.6)	18 (17.3 to 18.8)	59.4 (58.7 to 60)	51.9 (50.6 to 53.1)	58.8 (57 to 60.7)	77.3 (75.2 to 79.6)	60 (58.6 to 61.3)	58.4 (57.2 to 59.6)
Prostate Specific Antigen Test	67.6 (67.2 to 68)	29.2 (28.3 to 30.1)	53 (52.3 to 53.6)	45.1 (43.9 to 46.2)	51.7 (50 to 53.5)	47 (45.3 to 48.7)	59.2 (57.8 to 60.6)	57.6 (56.4 to 58.8)
Seen Breast Surgeon	1.5 (1.5 to 1.6)	0.6 (0.4 to 0.7)	0.4 (0.4 to 0.5)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)
Seen in Breast Clinic	26.5 (26.2 to 26.8)	14.3 (13.6 to 14.9)	21.8 (21.4 to 22.2)	19.3 (18.5 to 20)	24 (22.8 to 25.3)	19 (17.9 to 20.1)	24.6 (23.8 to 25.5)	21.9 (21.2 to 22.6)

Note. NR = counts <5 censored and so not reported.

 Table S14. Incidence rate ratios (with 95% confidence intervals) of screening and diagnostic tests compared to pre-pandemic period

Screening/Diagnostic Test	Lockdown (March 2020-June 2020)	Post-lockdown1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021- Dec 2021)
Biopsy of Breast	0.76 (0.67 to 0.86)	0.91 (0.81 to 1.02)	1.01 (0.86 to 1.18)	1.18 (1.02 to 1.37)	1.35 (1.21 to 1.49)	1.32 (1.2 to 1.44)
Biopsy of Prostate	0.69 (0.59 to 0.81)	0.68 (0.58 to 0.8)	1.08 (0.89 to 1.29)	0.98 (0.8 to 1.19)	1.08 (0.94 to 1.23)	1.05 (0.93 to 1.19)
Breast Cancer Referrals	0.64 (0.62 to 0.67)	0.91 (0.88 to 0.94)	0.94 (0.9 to 0.99)	0.86 (0.82 to 0.91)	0.96 (0.92 to 0.99)	0.92 (0.89 to 0.95)
Colonoscopy	0.35 (0.34 to 0.37)	0.57 (0.54 to 0.59)	0.73 (0.7 to 0.77)	0.76 (0.72 to 0.8)	0.84 (0.81 to 0.87)	0.79 (0.77 to 0.82)
Colorectal Cancer Referrals	0.58 (0.55 to 0.61)	0.89 (0.85 to 0.93)	0.89 (0.84 to 0.94)	0.83 (0.78 to 0.88)	1.02 (0.98 to 1.06)	0.95 (0.92 to 0.99)
Excision of Breast	0.71 (0.65 to 0.78)	0.73 (0.67 to 0.8)	1.02 (0.91 to 1.14)	0.79 (0.7 to 0.9)	0.92 (0.84 to 1)	0.93 (0.86 to 1)
Lung Cancer Referrals	0.51 (0.4 to 0.63)	0.69 (0.56 to 0.83)	0.58 (0.42 to 0.77)	0.63 (0.47 to 0.84)	0.81 (0.67 to 0.97)	0.64 (0.53 to 0.77)
Mammograms	0.23 (0.22 to 0.24)	0.66 (0.64 to 0.67)	0.74 (0.72 to 0.77)	0.98 (0.95 to 1.01)	0.76 (0.74 to 0.78)	0.74 (0.72 to 0.75)
PSA	0.43 (0.42 to 0.45)	0.67 (0.65 to 0.68)	0.77 (0.74 to 0.79)	0.69 (0.67 to 0.72)	0.88 (0.86 to 0.9)	0.85 (0.83 to 0.87)
Seen in Breast Clinic	0.54 (0.51 to 0.56)	0.73 (0.7 to 0.76)	0.91 (0.86 to 0.95)	0.72 (0.67 to 0.76)	0.93 (0.9 to 0.96)	0.83 (0.8 to 0.86)
Seen by Breast Surgeon	0.37 (0.29 to 0.46)	0.26 (0.19 to 0.34)	0.32 (0.22 to 0.45)	0.29 (0.19 to 0.42)	0.31 (0.23 to 0.4)	0.2 (0.14 to 0.27)
Sigmoidoscopy	0.3 (0.28 to 0.32)	0.42 (0.4 to 0.45)	0.62 (0.58 to 0.67)	0.64 (0.6 to 0.69)	0.64 (0.61 to 0.67)	0.51 (0.48 to 0.53)



Figure S4. Incidence Rates (with 95% confidence intervals) per 100,000 Person-Years of Breast Cancer Screening/ Diagnostic Tests/ Referrals in Months Before and After COVID-19 Lockdown (red dashed line)



Figure S5. Incidence Rates (with 95% confidence intervals) per 100,000 Person-Years of Colorectal Cancer Screening/ Diagnostic Tests/ Referrals in Months Before and After COVID-19 Lockdown (red dashed line)




Figure S6. Incidence Rates (with 95% confidence intervals) per 100,000 Person-Years of Lung Cancer Screening/ Diagnostic Tests/ Referrals in Months Before and After COVID-19 Lockdown (red dashed line)




Figure S7. Incidence Rates (with 95% confidence intervals) per 100,000 Person-Years of Prostate Cancer Screening/ Diagnostic Tests/ Referrals in Months Before and After COVID-19 Lockdown (red dashed line)




Figure S8: Incidence Rates per 100,000 Person-Years (with 95% confidence intervals) of Cancer Diagnoses in Months Before and After COVID-19 Lockdown (red dashed line)

Table S15. Incidence Rate Ratios (with 95% confidence intervals) for the cancer diagnoses, in each lockdown period, with the pre-pandemic era (Jan 2017 to Feb 2020) as a reference

Cancer	First Lockdown (March 2020-June 2020)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)
Breast	0.69 (0.63 to 0.74)	0.77 (0.71 to 0.83)	0.93 (0.84 to 1.02)	0.8 (0.72 to 0.89)	0.9 (0.84 to 0.97)	0.93 (0.87 to 0.99)
Colorectal	0.74 (0.67 to 0.81)	0.92 (0.84 to 1.01)	0.98 (0.87 to 1.1)	0.91 (0.8 to 1.03)	1.06 (0.97 to 1.15)	1.02 (0.94 to 1.1)
Lung	0.92 (0.84 to 1.01)	0.95 (0.87 to 1.03)	0.98 (0.86 to 1.1)	0.84 (0.73 to 0.96)	1.09 (1 to 1.19)	0.97 (0.89 to 1.05)
Prostate	0.71 (0.66 to 0.78)	0.72 (0.67 to 0.79)	0.82 (0.73 to 0.92)	0.82 (0.73 to 0.91)	0.9 (0.83 to 0.97)	0.8 (0.74 to 0.86)

Table S16. Observed incidence rates (with 95% confidence intervals) of breast cancer diagnoses in each of the time periods, overall and stratified by age and sex

Sex	Age Group (years)	Pre-pandemic (Jan 2017-Feb 2020)	First Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021	Legal restrictions removed (July 2021-Dec 2021)
Overall		7.1 (6.9 to 7.2)	4.9 (4.5 to 5.2)	6.2 (5.9 to 6.4)	5.4 (5 to 5.9)	6.6 (6 to 7.2)	5.7 (5.1 to 6.3)	6.4 (6 to 6.9)	6.6 (6.2 to 7)
Female	0;150	14 (13.7 to 14.3)	9.6 (8.9 to 10.4)	12.2 (11.8 to 12.6)	10.7 (10 to 11.6)	13.1 (11.8 to 14.4)	11.3 (10.1 to 12.5)	12.7 (11.8 to 13.6)	13 (12.3 to 13.9)
Female	20;39	2.1 (1.9 to 2.4)	2.1 (1.5 to 2.9)	2.2 (1.8 to 2.6)	1.7 (1.1 to 2.6)	2.8 (1.8 to 4.3)	1.9 (0.8 to 4)	2.2 (1.5 to 3.1)	2.4 (1.6 to 3.3)
Female	40;59	19.2 (18.6 to 19.8)	12.9 (11.3 to 14.6)	16.4 (15.5 to 17.3)	15.8 (14 to 17.8)	18 (15.3 to 21)	15.1 (12.6 to 18)	16.2 (14.3 to 18.2)	16.8 (15.1 to 18.6)
Female	60;79	30.7 (29.8 to 31.6)	19.9 (17.6 to 22.3)	25.3 (24 to 26.7)	20.9 (18.6 to 23.5)	27.6 (23.8 to 31.9)	24.3 (20.6 to 28.3)	26.2 (23.5 to 29.1)	27.8 (25.3 to 30.4)
Female	80;150	30.9 (29.2 to 32.6)	21.6 (17.4 to 26.5)	28.7 (26.1 to 31.4)	26.5 (21.7 to 32)	27.4 (20.5 to 36)	23.7 (17.4 to 31.5)	30.9 (25.6 to 36.9)	31.5 (26.5 to 37.1)
Male	0;150	0.3 (0.2 to 0.4)	NR	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.7)	NR	NR	NR	NR

Table S17. Observed incidence rates (with 95% confidence intervals) of colorectal cancer diagnoses in each of the time periods, overall and stratified by age and sex

Sex	Age Group (years)	Pre-pandemic (Jan 2017-Feb 2020)	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021	Legal restrictions removed (July 2021-Dec 2021)
Overall		4.5 (4.4 to 4.6)	3.3 (3 to 3.6)	4.4 (4.2 to 4.6)	4.1 (3.8 to 4.5)	4.4 (3.9 to 4.9)	4.1 (3.6 to 4.6)	4.7 (4.4 to 5.1)	4.5 (4.2 to 4.9)
Female	0;150	3.9 (3.7 to 4)	3 (2.6 to 3.5)	3.8 (3.5 to 4)	3.7 (3.3 to 4.2)	3.4 (2.8 to 4.1)	2.9 (2.3 to 3.6)	4.2 (3.7 to 4.7)	4 (3.6 to 4.5)
Female	20;39	NR	NR	1.3 (0.4 to 3.1)	NR	NR	NR	1.3 (0.4 to 3.1)	NR
Female	40;59	2.4 (2.2 to 2.7)	2.4 (1.7 to 3.2)	2.2 (1.9 to 2.6)	2.2 (1.6 to 3)	1.7 (1 to 2.8)	2.1 (1.3 to 3.4)	2.7 (2 to 3.6)	2.1 (1.5 to 2.9)
Female	60;79	10.2 (9.7 to 10.8)	6.7 (5.5 to 8.2)	9.4 (8.6 to 10.2)	9 (7.5 to 10.7)	8.8 (6.7 to 11.3)	6.2 (4.4 to 8.4)	9.7 (8.1 to 11.5)	11 (9.4 to 12.7)
Female	80;150	17.9 (16.7 to 19.2)	14.1 (10.8 to 18.1)	17.8 (15.9 to 20)	18.7 (14.7 to 23.4)	17.3 (11.9 to 24.3)	14.5 (9.7 to 20.9)	18.9 (14.9 to 23.8)	17.8 (14.2 to 22.1)
Male	0;150	5.1 (4.9 to 5.2)	3.6 (3.2 to 4.1)	5.1 (4.8 to 5.3)	4.5 (4 to 5.1)	5.3 (4.6 to 6.2)	5.2 (4.5 to 6.1)	5.3 (4.8 to 5.9)	5.1 (4.6 to 5.6)
Male	40;59	2.8 (2.6 to 3.1)	2.6 (1.7 to 3.8)	3 (2.6 to 3.4)	2.2 (1.6 to 3)	2.9 (1.9 to 4.2)	3 (2 to 4.4)	3.4 (2.6 to 4.3)	3.6 (2.8 to 4.5)
Male	60;79	15.3 (14.6 to 16)	10.7 (9 to 12.6)	14.4 (13.4 to 15.4)	13.1 (11.2 to 15.2)	16.9 (13.8 to 20.4)	15.5 (12.6 to 18.9)	14.7 (12.7 to 17)	13.7 (11.9 to 15.6)
Male	80;150	28.7 (26.8 to 30.7)	21 (16.1 to 26.9)	26.7 (23.7 to 29.9)	29.3 (23.3 to 36.4)	24.8 (17 to 35)	22.5 (15.3 to 32)	28.3 (22.3 to 35.5)	25.5 (20.2 to 31.7)

Sex	Age Group (years)	Pre-pandemic (Jan 2017-Feb 2020)	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021	Legal restrictions removed (July 2021-Dec 2021)
Overall		4.2 (4.1 to 4.3)	3.9 (3.5 to 4.2)	4.1 (3.9 to 4.3)	4 (3.6 to 4.3)	4.1 (3.6 to 4.6)	3.5 (3 to 4)	4.6 (4.2 to 5)	4.1 (3.7 to 4.4)
Female	0;150	4.2 (4.1 to 4.4)	3.8 (3.4 to 4.3)	4.1 (3.9 to 4.4)	4.1 (3.6 to 4.6)	4.1 (3.4 to 4.8)	3.6 (3 to 4.4)	4.5 (4 to 5.1)	4 (3.6 to 4.5)
Female	40;59	1.7 (1.6 to 1.9)	1.5 (1 to 2.2)	2 (1.6 to 2.4)	1.8 (1.2 to 2.7)	2 (1.2 to 3.2)	2 (0.9 to 4)	1.9 (1.2 to 2.8)	2.2 (1.5 to 3)
Female	60;79	13.1 (12.5 to 13.7)	11.3 (9.6 to 13.2)	12.3 (11.4 to 13.3)	12.3 (10.5 to 14.3)	11.8 (9.3 to 14.7)	11.3 (8.9 to 14.1)	13.3 (11.4 to 15.4)	12.2 (10.6 to 14)
Female	80;150	16.8 (15.6 to 18.1)	15.7 (12.2 to 19.9)	15.9 (14.1 to 18)	17.4 (13.6 to 22)	16.8 (11.5 to 23.7)	12 (7.7 to 17.9)	18.9 (14.8 to 23.7)	13.4 (10.3 to 17.2)
Male	0;150	4.2 (4 to 4.3)	3.9 (3.5 to 4.4)	4.1 (3.8 to 4.3)	3.8 (3.3 to 4.3)	4.1 (3.4 to 4.9)	3.4 (2.8 to 4.1)	4.6 (4.1 to 5.2)	4.1 (3.6 to 4.6)
Male	40;59	1.5 (1.4 to 1.7)	1.6 (1.1 to 2.3)	1.8 (1.4 to 2.3)	1.8 (1.2 to 2.6)	2.4 (1.2 to 4.3)	NR	1.4 (0.7 to 2.4)	1.9 (1.2 to 2.8)
Male	60;79	13.7 (13 to 14.3)	11.5 (9.7 to 13.4)	13 (12.1 to 14)	12 (10.2 to 14)	13.5 (10.8 to 16.7)	12.5 (9.9 to 15.5)	14 (12 to 16.2)	13 (11.3 to 15)
Male	80;150	25.3 (23.5 to 27.2)	25.3 (19.9 to 31.7)	24.3 (21.5 to 27.3)	22.4 (17.2 to 28.7)	23.2 (15.6 to 33.1)	16.7 (10.6 to 25)	29.7 (23.6 to 37)	25.1 (19.9 to 31.3)

Table S18. Observed incidence rates (with 95% confidence intervals) of lung cancer diagnoses in each of the time periods, overall and stratified by age and sex

Table S19. Observed incidence rates (with 95% confidence intervals) of prostate cancer diagnoses in each of the time periods, overall and stratified by age and sex

Sex	Age Group (years)	Pre-pandemic (Jan 2017-Feb 2020)	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)
Overall		6.2 (6.1 to 6.3)	4.4 (4.1 to 4.8)	5 (4.8 to 5.2)	4.5 (4.1 to 4.9)	5.1 (4.6 to 5.7)	5.1 (4.5 to 5.7)	5.6 (5.2 to 6)	5 (4.6 to 5.3)
Male	0;150	12.5 (12.3 to 12.8)	8.9 (8.2 to 9.7)	10.1 (9.7 to 10.5)	9.1 (8.3 to 9.8)	10.3 (9.2 to 11.5)	10.2 (9.1 to 11.4)	11.3 (10.4 to 12.1)	10.1 (9.4 to 10.8)
Male	40;59	4.8 (4.5 to 5.1)	2.8 (2.1 to 3.6)	3.1 (2.7 to 3.5)	2.3 (1.7 to 3.1)	3.2 (2.2 to 4.6)	3.7 (2.5 to 5.2)	3.9 (3.1 to 5)	2.8 (2.1 to 3.6)
Male	60;79	45.5 (44.4 to 46.7)	33.1 (30.1 to 36.3)	35.9 (34.3 to 37.5)	32.7 (29.7 to 35.9)	37.3 (32.7 to 42.4)	34.7 (30.2 to 39.6)	39.3 (35.9 to 43)	35.8 (32.9 to 38.8)
Male	80;150	55.5 (52.9 to 58.3)	34.1 (27.8 to 41.5)	44.7 (40.9 to 48.8)	44.6 (37 to 53.2)	47.7 (36.5 to 61.3)	44 (33.6 to 56.7)	44.4 (36.7 to 53.2)	44.1 (37 to 52.2)

Figure S9. Incidence Rates per 100,000 Person-Years (with 95% confidence intervals) of Cancer Diagnoses in Months Before and After COVID-19 Lockdown (red dashed line) Stratified by Age and Sex



 Table S20.
 Observed incidence rate ratios (with 95% confidence intervals) of breast cancer diagnoses in each of the time periods stratified by age and sex

Sex	Age Group (years)	First Lockdown (March 2020-June 2020)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021	Legal restrictions removed (July 2021-Dec 2021)
Female	20;39	0.98 (0.69 to 1.37)	0.81 (0.51 to 1.22)	1.33 (0.85 to 1.99)	0.92 (0.39 to 1.8)	1.02 (0.7 to 1.43)	1.1 (0.76 to 1.54)
Female	40;59	0.67 (0.59 to 0.76)	0.82 (0.73 to 0.93)	0.94 (0.8 to 1.1)	0.79 (0.66 to 0.94)	0.84 (0.74 to 0.95)	0.88 (0.79 to 0.97)
Female	60;79	0.65 (0.57 to 0.73)	0.68 (0.6 to 0.77)	0.9 (0.77 to 1.04)	0.79 (0.67 to 0.92)	0.85 (0.76 to 0.95)	0.9 (0.82 to 0.99)
Female	80;150	0.7 (0.56 to 0.86)	0.86 (0.7 to 1.04)	0.89 (0.67 to 1.16)	0.77 (0.57 to 1.02)	1 (0.83 to 1.2)	1.02 (0.86 to 1.21)

Sex	Age Group (years)	Lockdown (March 2020-June 2020)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021	Legal restrictions removed (July 2021- Dec 2021)
Female	40;59	0.98 (0.71 to 1.31)	0.9 (0.64 to 1.22)	0.71 (0.4 to 1.14)	0.88 (0.53 to 1.37)	1.12 (0.82 to 1.5)	0.87 (0.63 to 1.18)
Female	60;79	0.66 (0.53 to 0.8)	0.88 (0.73 to 1.05)	0.86 (0.66 to 1.11)	0.6 (0.44 to 0.81)	0.95 (0.79 to 1.13)	1.07 (0.92 to 1.25)
Female	80;150	0.79 (0.6 to 1.02)	1.05 (0.82 to 1.32)	0.97 (0.67 to 1.35)	0.82 (0.55 to 1.16)	1.06 (0.83 to 1.34)	1 (0.79 to 1.25)
Male	40;59	0.91 (0.6 to 1.33)	0.77 (0.55 to 1.04)	1.02 (0.67 to 1.48)	1.06 (0.7 to 1.54)	1.19 (0.9 to 1.54)	1.26 (0.98 to 1.6)
Male	60;79	0.7 (0.59 to 0.82)	0.86 (0.73 to 1)	1.11 (0.9 to 1.33)	1.01 (0.82 to 1.24)	0.96 (0.83 to 1.12)	0.9 (0.78 to 1.03)
Male	80;150	0.73 (0.56 to 0.94)	1.02 (0.81 to 1.28)	0.87 (0.6 to 1.21)	0.79 (0.54 to 1.11)	0.99 (0.78 to 1.24)	0.89 (0.7 to 1.11)

Table S21. Observed incidence rate ratios (with 95% confidence intervals) of colorectal cancer diagnoses in each of the time periods, stratified by age and sex

Table S22. Observed incidence rate ratios (with 95% confidence intervals) of lung cancer diagnoses in each of the time periods, stratified by age and sex

Sex	Age Group (years)	Lockdown (March 2020-June 2020)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)
Female	40;59	0.88 (0.59 to 1.27)	1.04 (0.68 to 1.53)	1.18 (0.71 to 1.84)	1.17 (0.53 to 2.21)	1.1 (0.71 to 1.62)	1.25 (0.87 to 1.74)
Female	60;79	0.86 (0.73 to 1.01)	0.94 (0.8 to 1.1)	0.9 (0.71 to 1.12)	0.86 (0.68 to 1.08)	1.01 (0.87 to 1.18)	0.93 (0.81 to 1.07)
Female	80;150	0.94 (0.72 to 1.19)	1.04 (0.81 to 1.31)	1 (0.69 to 1.4)	0.72 (0.47 to 1.05)	1.13 (0.88 to 1.42)	0.8 (0.61 to 1.03)
Male	40;59	1.07 (0.73 to 1.52)	1.16 (0.75 to 1.71)	1.58 (0.81 to 2.74)	NR	0.9 (0.48 to 1.53)	1.22 (0.78 to 1.83)
Male	60;79	0.84 (0.71 to 0.99)	0.88 (0.75 to 1.03)	0.99 (0.79 to 1.22)	0.91 (0.72 to 1.14)	1.02 (0.88 to 1.19)	0.96 (0.82 to 1.1)
Male	80;150	1 (0.79 to 1.26)	0.89 (0.68 to 1.14)	0.92 (0.63 to 1.3)	0.66 (0.43 to 0.98)	1.18 (0.93 to 1.47)	0.99 (0.78 to 1.25)

Note. NR = counts <5 censored and so not reported.

Table S23. Observed incidence rate ratios (with 95% confidence intervals) of prostate cancer diagnoses in each of the time periods, stratified by age and sex

Sex	Age Group (years)	Lockdown (March 2020-June 2020)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021- Dec 2021)
Male	40;59	0.58 (0.44 to 0.76)	0.49 (0.36 to 0.66)	0.68 (0.46 to 0.96)	0.78 (0.54 to 1.09)	0.83 (0.64 to 1.05)	0.58 (0.44 to 0.75)
Male	60;79	0.73 (0.66 to 0.8)	0.72 (0.65 to 0.79)	0.82 (0.72 to 0.93)	0.76 (0.66 to 0.87)	0.86 (0.79 to 0.95)	0.79 (0.72 to 0.86)
Male	80;150	0.62 (0.5 to 0.75)	0.8 (0.66 to 0.96)	0.86 (0.66 to 1.1)	0.79 (0.61 to 1.02)	0.8 (0.66 to 0.96)	0.8 (0.66 to 0.94)


Table S24. Estimated percentage reduction, and estimated underdiagnoses (missed counts) (with 95% confidence intervals) for each cancer across the extended lockdown periods from the negative binomial modelling

Cancer	Parameter	First Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021- June 2021)	Legal restrictions removed (July 2021- Dec 2021)	Total (March 2020-Dec 2021)
Breast	Percent reduction	32% (19.5 to 41.9)	14.3% (-3.7 to 27.7)	22.2% (7 to 33.8)	4.9% (-14.2 to 19.2)	20.6% (4.4 to 32.7)	15% (-3.6 to 28.5)	8.1% (-12.2 to 23.4)	17.9% (1.1 to 30.6)
Breast	N underdiagnoses	311 (160 to 475)	541 (-117 to 1246)	204 (54 to 366)	22 (-52 to 99)	90 (16 to 168)	138 (-27 to 311)	88 (-108 to 302)	852 (43 to 1721)
Colorectal	Percent reduction	33.9% (18.1 to 45.4)	14.1% (-7.5 to 30.3)	16.4% (-3.6 to 31.1)	4.1% (-19.2 to 22.1)	20.2% (1.2 to 34.7)	14.1% (-8.2 to 30.7)	13.6% (-9.3 to 30.7)	18.1% (-2.4 to 33.3)
Colorectal	N underdiagnoses	230 (99 to 373)	385 (-164 to 1019)	107 (-19 to 246)	12 (-45 to 79)	63 (3 to 132)	95 (-44 to 256)	109 (-59 to 306)	615 (-65 to 1392)
Lung	Percent reduction	15.4% (-5.2 to 30.4)	13.9% (-9.4 to 30.4)	12.9% (-9.4 to 28.5)	7.3% (-16.1 to 24.4)	25.5% (6.1 to 39.2)	8.4% (-17.1 to 26.5)	17.2% (-6.8 to 33.9)	14.2% (-8.6 to 30.4)
Lung	N underdiagnoses	96 (-26 to 229)	349 (-187 to 946)	77 (-45 to 209)	20 (-36 to 84)	73 (14 to 138)	51 (-81 to 200)	128 (-39 to 315)	445 (-213 to 1175)
Prostate	Percent reduction	28.6% (8.9 to 42.7)	22.2% (-0.7 to 38.3)	28.5% (8.9 to 42.4)	18.1% (-4.9 to 34.4)	25.5% (6.1 to 40.1)	13.9% (-13.3 to 32.5)	23.7% (-0.1 to 40.4)	23.4% (1.2 to 39.2)
Prostate	N underdiagnoses	241 (59 to 449)	755 (-18 to 1647)	237 (58 to 438)	71 (-15 to 170)	106 (20 to 207)	110 (-80 to 328)	231 (-1 to 504)	997 (41 to 2096)

Cancer	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-first lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020- Dec 2021)
Breast	6,714	11,680	4,404	475	1,943	2,979	1,900	18,395
Colorectal	4,966	8,312	2,310	259	1,360	2,051	2,353	13,278
Lung	2,073	7,535	1,662	432	1,576	1,101	2,764	9,608
Prostate	5,203	16,300	5,117	1,533	2,289	2,375	4,987	21,525

Table S25. Estimated number of underdiagnosed cancer cases, extrapolated to the UK general population over each lockdown period





B) Colorectal Cancer

Figure S10. Expected and observed incidence rates per 100,000 person months of A) breast cancer, B) colorectal cancer, C) lung cancer, and D) prostate cancer in primary care records from CPRD GOLD UK, after lockdown, stratified by age and sex. Points represent monthly incidence rates. Expected rates (with 95% prediction intervals represented by shaded areas) were calculated using negative binomial regression using observed data from January 2017 to February 2020 to estimate expected counts from March 2020 to November 2021.



B) Colorectal Cancer




Figure S11. Incidence Rates per 100,000 Person-Years (with 95% confidence intervals) of Cancer Diagnoses in Months Before and After COVID-19 Lockdown (red dashed line) Stratified by UK Region

Table S26. Estimated percentage reduction, and estimated underdiagnoses (missed counts) (with 95% confidence intervals) for breast cancer across the extended lockdown periods from the negative binomial modelling, stratified by age and sex

Sex/Age Group	Parameter	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020-Dec 2021)
Female: 20;39	Percent reduction	23.2% (-140 to 64)	42.6% (-63 to 73.3)	47.4% (-37.5 to 72.5)	19.9% (-130 to 61.7)	51.9% (-16.7 to 75)	38.2% (-106.2 to 74.2)	50.7% (-36 to 77.3)	39.1% (-76.1 to 71.6)
Female: 20;39	N underdiagnoses	11 (-21 to 64)	88 (-46 to 327)	20 (-6 to 58)	6 (-13 to 37)	8 (-1 to 21)	20 (-17 to 95)	35 (-9 to 116)	99 (-67 to 391)
Female: 40;59	Percent reduction	28.5% (3.2 to 44.7)	6.4% (-29.7 to 29.8)	9.4% (-23.6 to 30.6)	-4% (-41.4 to 20.7)	15.8% (-16.5 to 36.2)	11.5% (-23.7 to 34.5)	-0.4% (-41.3 to 26.1)	11% (-22.7 to 32.9)
Female: 40;59	N underdiagnoses	96 (8 to 196)	81 (-273 to 506)	30 (-55 to 127)	-6 (-46 to 41)	24 (-18 to 72)	35 (-52 to 143)	-1 (-102 to 123)	178 (-265 to 702)
Female: 60;79	Percent reduction	37.4% (18.4 to 50.3)	18.6% (-9.1 to 36.8)	30.9% (9.7 to 45.5)	7.6% (-22.7 to 27.6)	21% (-4.6 to 38.2)	21.1% (-6.5 to 39)	9.6% (-24.3 to 30.8)	22.5% (-3.4 to 39.5)
Female: 60;79	N underdiagnoses	170 (64 to 287)	329 (-120 to 835)	130 (31 to 242)	15 (-34 to 70)	43 (-7 to 99)	92 (-21 to 221)	49 (-89 to 203)	498 (-56 to 1122)
Female: 80;150	Percent reduction	27.1% (-20.8 to 51.3)	6.8% (-61.5 to 39.9)	13.1% (-46.6 to 42.5)	17.6% (-36.8 to 45.3)	14.1% (-51.6 to 43.4)	-2.7% (-81.8 to 35.1)	1.5% (-73.5 to 38.2)	10.9% (-53 to 42.1)
Female: 80;150	N underdiagnoses	35 (-16 to 98)	34 (-179 to 312)	16 (-34 to 79)	11 (-14 to 43)	8 (-16 to 36)	-3 (-54 to 65)	2 (-61 to 89)	69 (-195 to 410)

Table S27. Estimated percentage reduction, and estimated underdiagnoses (missed counts) (with 95% confidence intervals) for colorectal cancer across the extended lockdown periods from the negative binomial modelling, stratified by age and sex

Sex/Age Group	Parameter	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020-Dec 2021)	
Male: 40;59	Percent reduction	5.8% (-127.3 to 49)	-5.8% (-174.4 to 45)	23.4% (-86.4 to 58.2)	2% (-136.4 to 46.9)	-15% (-225 to 38.1)	-16.6% (-205.3 to 42)	-22.7% (-236.4 to 38.3)	-4.5% (-168.8 to 45.4)	
Male: 40;59	N underdiagnoses	2 (-14 to 24)	-12 (-143 to 184)	13 (-19 to 57)	1 (-15 to 23)	-3 (-18 to 16)	-8 (-39 to 42)	-14 (-52 to 46)	-11 (-157 to 208)	
Male: 60;79	Percent reduction	23.1% (-15.9 to 45.3)	3.6% (-47.1 to 32.1)	14.5% (-24.5 to 38.4)	-20.6% (-87.7 to 14.4)	2.4% (-46.3 to 29)	-3.5% (-64.6 to 28.7)	9.1% (-40 to 37.1)	7.3% (-41.1 to 34.6)	
Male: 60;79	N underdiagnoses	44 (-20 to 121)	29 (-250 to 369)	29 (-34 to 108)	-18 (-50 to 18)	2 (-31 to 40)	-6 (-73 to 75)	22 (-62 to 128)	73 (-270 to 490)	
Male: 80;150	Percent reduction	33.5% (-26.5 to 59.7)	22.4% (-57.1 to 54.5)	2.1% (-97.6 to 42.1)	38.7% (-18.5 to 61.4)	23.9% (-55 to 54.4)	21.4% (-58.3 to 55)	29.9% (-45.5 to 60)	24.5% (-50.8 to 55.5)	
Male: 80;150	N underdiagnoses	31 (-13 to 92)	86 (-109 to 360)	2 (-40 to 59)	20 (-5 to 51)	10 (-11 to 37)	21 (-28 to 93)	34 (-25 to 120)	118 (-122 to 452)	
Female: 40;59	Percent reduction	22.9% (-87.5 to 57.9)	19.8% (-128.2 to 60.1)	18.7% (-110.5 to 57.4)	14.2% (-200 to 60.5)	16.7% (-157.1 to 57.1)	19.3% (-109.1 to 59.6)	24% (-138.9 to 63.6)	20.5% (-117.9 to 59.6)	
Female: 40;59	N underdiagnoses	13 (-21 to 62)	40 (-91 to 244)	9 (-21 to 54)	2 (-10 to 23)	4 (-11 to 24)	11 (-24 to 68)	14 (-25 to 75)	53 (-112 to 306)	
Female: 60;79	Percent reduction	45.8% (16.4 to 62.3)	25.1% (-22 to 50)	21.8% (-24.8 to 45.9)	19.7% (-31.1 to 44.9)	46.8% (14.6 to 64)	30.6% (-13.2 to 53.9)	16.8% (-38.3 to 46.2)	29.3% (-13.9 to 52.3)	
Female: 60;79	N underdiagnoses	82 (19 to 160)	178 (-96 to 531)	35 (-25 to 107)	14 (-14 to 48)	36 (7 to 73)	57 (-15 to 151)	36 (-49 to 152)	260 (-77 to 691)	
Female: 80;150	Percent reduction	33.6% (-24.5 to 59.1)	20.5% (-60.7 to 53.6)	19.9% (-49 to 50.6)	-7.8% (-135.7 to 38.9)	30.4% (-38.1 to 57.4)	21.3% (-60.9 to 55.4)	24.4% (-60.8 to 57.1)	23.1% (-53 to 54.6)	
Female: 80;150	N underdiagnoses	31 (-12 to 88)	76 (-111 to 339)	19 (-25 to 78)	-2 (-19 to 21)	13 (-8 to 39)	20 (-28 to 92)	26 (-31 to 109)	106 (-123 to 427)	

Table S28. Estimated percentage reduction, and estimated underdiagnoses (missed counts) (with 95% confidence intervals) for lung cancer across the extended lockdown periods from the negative binomial modelling, stratified by age and sex

Sex/Age Group	Parameter	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020-Dec 2021)
Male: 40;59	Percent reduction	-12.1% (-357.1 to 49.2)	-22.2% (-491.7 to 50.7)	-26.9% (-525 to 46.8)	-111.9% (-1000 to 15.4)	NR	15.2% (-300 to 65.7)	-20.5% (-475 to 53.1)	-18.8% (-442.1 to 50.2)
Male: 40;59	N underdiagnoses	-3 (-25 to 31)	-13 (-59 to 73)	-5 (-21 to 22)	-6 (-10 to 2)	NR	2 (-9 to 23)	-4 (-19 to 26)	-16 (-84 to 104)
Male: 60;79	Percent reduction	31% (-1.9 to 50.2)	25.5% (-13.3 to 48.1)	24.5% (-12 to 46.3)	10% (-38.7 to 36.8)	28.2 (-6.8 to 48.7)	26.4% (-12 to 49.7)	29.5% (-9.3 to 51.6)	26.5% (-11 to 48.5)
Male: 60;79	N underdiagnoses	71 (-3 to 158)	239 (-82 to 649)	52 (-17 to 137)	10 (-24 to 50)	31 (-5 to 75)	63 (-19 to 175)	83 (-17 to 212)	310 (-85 to 807)
Male: 80;150	Percent reduction	10.5% (-74.4 to 45.3)	18% (-72.3 to 52.9)	26.8% (-44.2 to 55.7)	9.4% (-87.5 to 48.3)	29.9 (-43.8 to 59.6)	2.8% (-110.5 to 45.6)	21.8% (-71.7 to 56.1)	16.5% (-72.8 to 51.5)
Male: 80;150	N underdiagnoses	9 (-32 to 62)	60 (-115 to 308)	23 (-19 to 78)	3 (-14 to 28)	10 (-7 to 34)	2 (-42 to 67)	22 (-33 to 101)	69 (-147 to 370)
Female: 40;59	Percent reduction	17.9% (-163.6 to 60.8)	2.9% (-243.8 to 56.7)	13.1% (-177.8 to 57.6)	-18.9% (-350 to 43.8)	-7.8 (-300 to 50)	9.1% (-242.9 to 61.9)	1.5% (-250 to 58.3)	6.5% (-223.3 to 57.6)
Female: 40;59	N underdiagnoses	6 (-18 to 45)	3 (-78 to 144)	4 (-16 to 34)	-3 (-14 to 14)	-1 (-6 to 8)	2 (-17 to 39)	1 (-25 to 49)	10 (-96 to 189)
Female: 60;79	Percent reduction	6.5% (-46.8 to 34.8)	2.6% (-55.7 to 32.7)	3.6% (-48.3 to 31.7)	11.9% (-38.6 to 36.3)	8.2 (-44.2 to 35.9)	-8.8% (-78.8 to 26.9)	4.4% (-56.9 to 35.2)	3.3% (-54 to 33.1)
Female: 60;79	N underdiagnoses	11 (-52 to 87)	19 (-253 to 343)	6 (-56 to 80)	11 (-22 to 45)	7 (-23 to 42)	-14 (-78 to 65)	9 (-74 to 111)	30 (-305 to 430)
Female: 80;150	Percent reduction	7.1% (-88.9 to 44.7)	5% (-112.1 to 47.2)	-4.6% (-121.9 to 38.8)	3.8% (-113.3 to 45.8)	21.7 (-71.4 to 56.4)	-9.5% (-146.7 to 40.3)	19.9% (-87.9 to 56.9)	5.4% (-106.9 to 46.7)
Female: 80;150	N underdiagnoses	5 (-32 to 55)	14 (-139 to 235)	-3 (-39 to 45)	1 (-17 to 27)	7 (-10 to 31)	-6 (-44 to 50)	15 (-29 to 82)	19 (-171 to 290)

Table 29. Estimated percentage reduction, and estimated underdiagnoses (missed counts) (with 95% confidence intervals) for prostate cancer across the extended lockdown periods from the negative binomial modelling, stratified by age and sex

Sex/Age Group	Parameter	Lockdown (March 2020-June 2020)	Post-lockdown (July 2020-Dec 2021)	Post-lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021-June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020-Dec 2021)
Male: 40;59	Percent reduction	35.3% (-22.7 to 60)	24.5% (-54.4 to 55.1)	40.3% (-15.8 to 63.9)	34.5% (-20.8 to 58.6)	1.9% (-113.3 to 40.7)	4.4% (-106.1 to 44.7)	31.2% (-46.2 to 60.1)	26.8% (-47.2 to 56.1)
Male: 40;59	N underdiagnoses	29 (-10 to 81)	75 (-81 to 282)	30 (-6 to 78)	15 (-5 to 41)	1 (-17 to 22)	3 (-35 to 55)	26 (-18 to 86)	104 (-91 to 363)
Male: 60;79	Percent reduction	25.8% (2.8 to 42)	22.4% (-3.2 to 40)	28.9% (7.2 to 44.2)	19.1% (-7.8 to 36.6)	27.3% (5.2 to 42.9)	14% (-15.8 to 35)	22.9% (-3.8 to 40.9)	23% (-2 to 40.4)
Male: 60;79	N underdiagnoses	156 (13 to 324)	552 (-59 to 1280)	173 (33 to 338)	55 (-17 to 135)	82 (12 to 163)	80 (-67 to 264)	163 (-20 to 380)	708 (-46 to 1604)
Male: 80;150	Percent reduction	34.4% (-3.1 to 55)	19.3% (-33.9 to 45.8)	20.9% (-27.1 to 45)	-1.9% (-74.3 to 32.2)	26.9% (-15.4 to 49.6)	18.2% (-37.2 to 46.4)	22.5% (-33 to 48.9)	22.3% (-27.5 to 47.6)
Male: 80;150	N underdiagnoses	52 (-3 to 122)	119 (-126 to 421)	32 (-26 to 100)	-1 (-26 to 29)	22 (-8 to 59)	26 (-32 to 102)	40 (-34 to 131)	172 (-129 to 543)

Cancer	Sex/Age Group	Lockdown (March 2020- June 2020)	Post-lockdown (July 2020-Dec 2021)	Post- lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021- June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020-Dec 2021)
Breast									
	Female: 20;39	237	1,900	432	130	173	432	756	2,137
	Female: 40;59	2,073	1,749	648	-130	518	756	-22	3,843
	Female: 60;79	3,670	7,103	2,807	324	928	1,986	1,058	10,752
	Female: 80;150	756	734	345	237	173	-65	43	1,490
Colorectal									
	Male: 40;59	43	-259	281	22	-65	-173	-302	-237
	Male: 60;79	950	626	626	-389	43	-130	475	1,576
	Male: 80;150	669	1,857	43	432	216	453	734	2,548
	Female: 40;59	281	864	194	43	86	237	302	1,144
	Female: 60;79	1,770	3,843	756	302	777	1,231	777	5,613
	Female: 80;150	669	1,641	410	-43	281	432	561	2,289
Lung									
	Male: 40;59	-65	-281	-108	-130	NR	43	-86	-345
	Male: 60;79	1,533	5,160	1,123	216	669	1,360	1,792	6,693
	Male: 80;150	194	1,295	497	65	216	43	475	1,490

Table S30. Estimated number of underdiagnosed cancer cases, extrapolated to the UK general population over each lockdown period, stratified by age and sex

Table S30. Estimated number of underdiagnosed cancer cases, extrapolated to the UK general population over each lockdown period, stratified by age and sex

Cancer	Sex/Age Group	Lockdown (March 2020- June 2020)	Post-lockdown (July 2020-Dec 2021)	Post- lockdown 1 (July 2020-Oct 2020)	Second lockdown (Nov 2020-Dec 2020)	Third lockdown (Jan 2021-Feb 2021)	Easing of restrictions (March 2021- June 2021)	Legal restrictions removed (July 2021-Dec 2021)	Total (March 2020-Dec 2021)
	Female: 40;59	130	65	86	-65	-22	43	22	216
	Female: 60;79	237	410	130	237	151	-302	194	648
	Female: 80;150	108	302	-65	22	151	-130	324	410
Prostate									
	Male: 40;59	626	1,619	648	324	22	65	561	2,245
	Male: 60;79	3,368	11,918	3,735	1,187	1,770	1,727	3,519	15,286
	Male: 80;150	1,123	2,569	691	-22	475	561	864	3,713